Lecanemab (lecanemab)-LEQEMBI current price and market reference prices of different specifications and drug purchase channels

Lencanezumab (LEQEMBI) has been approved for marketing in China and is mainly used for the treatment of patients with mild cognitive impairment and early Alzheimer's disease. However, the drug has not yet been included in the medical insurance catalog, so the cost for patients to purchase it at home is relatively high. At the same time, supply channels are limited, making it relatively difficult to purchase the drug. Before considering using it, patients need to fully understand the price, usage and accessibility of the drug so that they can reasonably plan their treatment plan and financial budget.

In overseas markets, LEQEMBI ’s US version of the original drug costs approximately more than 10,000 yuan per box. The specific cost will fluctuate depending on exchange rates and import channels. The drug is administered as an intravenous injection, usually every two weeks, and the specific dose is adjusted based on the patient's weight and condition. Due to the special method of administration, patients also need to consider the cost of infusion operations and related medical service costs, which further increases the overall treatment cost.

In the domestic market, although the available specifications are usually 200mg/2mL per bottle, patients need to pay the full amount out of pocket as there is no medical insurance reimbursement. During the actual treatment process, each administration may require multiple bottles of medicine, and the total cost of long-term maintenance treatment is high. Therefore, families should evaluate their financial affordability before use and discuss the most reasonable treatment cycle and dosage arrangement with the attending doctor and pharmacist to reduce unnecessary financial pressure.

As for drug purchase channels, patients can obtain them through regular hospital pharmacies or imported drug channels. They can also pay attention to clinical trials, assistance projects or special import policies, which may provide financial support to some patients. Taken together, although LEQEMBI has potential clinical efficacy, it is expensive, not covered by medical insurance, and difficult to purchase. Patients should fully consider the drug's effect, accessibility, and long-term treatment costs before taking the drug to ensure safe, reasonable, and sustainable treatment.

Reference materials:https://en.wikipedia.org/wiki/Lecanemab